Table 5.
Fact box of the side-effects and benefits of CRC surveillance
| Variable | Surveillance effects |
|---|---|
|
Resource use
| |
| Analysed surveillance months |
110 patients for 1884 months |
| Cost per successful R0 resection (£) |
103207 |
|
Screening tests per R0 metastases resection | |
| Carcinoembryonic antigen CEA (n) |
125 |
| Chest x-ray (n) |
70 |
| Liver ultrasound (n) |
52 |
| Colonoscopies (n) |
30 |
| Total screening tests (n) |
276 |
| Total health care consultations (n) |
296 |
|
Benefits
| |
| Number of cancer recurrences detected (n) |
14 |
| Probability of R0 metastasis surgery (%)* |
57% (4 of 7 metastasis surgeries) |
|
Side effects
|
|
| False positive events (n) |
34 (31%) |
| Probability of recurrent cancer when diagnostic check up i.e. surveillance positive predictive value |
29% |
|
a
Mean days to SCE diagnosis (SD) |
39 (35) |
| Asymptomatic but incurable metastases recurrences |
3 of 14 recurrences (21%) |
|
Quality of life
| |
|
aMean EQ-5D VAS score (CI) |
75.9 (74.5-77.3) |
| aMean EQ-5D Index score (CI) | 0.862 (0.84-0.87) |